Elephas Biosciences Secures $40M Series B-2 Funding to Advance Live Tumor Profiling Platform

Why It Matters

The capital infusion accelerates development and commercialization of a technology that could dramatically improve patient selection for immunotherapies, reducing costly trial-and‑error and expanding market adoption. Successful deployment would address a critical gap in oncology, potentially improving outcomes and lowering healthcare costs.

Deal Summary

Elephas Biosciences announced a $40 million Series B-2 round to scale its live tumor profiling technology for immunotherapy response prediction. Existing backers including Northpond Ventures, ARCH Venture Partners, the State of Wisconsin Investment Board, Tao Capital Partners, Sands Capital and Venture Investors Health Fund participated in the equity round.